Welcome To Campus Sanofi Singapore

The programme brought together international and local experts to discuss the evolving understanding of Type 2 inflammation in atopic dermatitis, with a focus on IL-4 and IL-13, disease modification, and the importance of early intervention across different patient populations. 

The United in Rare: Advancing LSDs Care across Asia event was held on the 22nd to 23rd November 2025 in Bangkok, Thailand. The event aimed to provide a platform for experts across Thailand, Malaysia, Singapore, Taiwan, South Korea and India to share their experiences in management of LSDs by discussing challenges cases and best practices to improve diagnosis and treatment pathways for LSDs.

Nearly 1 in 3 patients with uncontrolled moderate‑to‑severe type 2 asthma achieved clinical remission with dupilumab. Our latest update highlights key QUEST/TRAVERSE data, remission criteria, and implications for practice.

An overview of DUPIXENT

LIBERTY AD CHRONOS was a randomized, double-blind, placebo-controlled trial in adults with 
moderate-to-severe atopic dermatitis

LIBERTY AD SOLO-CONTINUE was a randomized, double-blind, phase 3 clinical trial at 185 sites in North America, Europe, Asia, and Japan.

LIBERTY AD HAFT was a randomized phase 3 trial in adults and adolescents with moderate-to-severe hand and foot atopic dermatitis inadequately controlled with topicals.